Impact of the Omics-Based Biomarkers on the Fluvoxamine’s Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder

INTRODUCTION: Fluvoxamine is commonly administered to patients with recurrent depressive disorder. Some of these patients do not show adequate response to the therapy with fluvoxamine, whereas many of them experience dose-dependent adverse drug reactions. Previous research revealed that CYP2D6 is in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Psychopharmacol Bull
Autori principali: Zastrozhin, MS, Skryabin, VYu, Smirnov, VYu, Zastrozhina, AK, Kaverina, EV, Klepikov, DA, Grishina, EA, Ryzhikova, KA, Bure, IV, Bryun, EA, Sychev, DA
Natura: Artigo
Lingua:Inglês
Pubblicazione: MedWorks Media Global 2021
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8063127/
https://ncbi.nlm.nih.gov/pubmed/33897064
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi